COX-2 selective inhibitors - Important lessons learned

Lancet

Volumn 365, Issue 9458, 2005, Pages 449-451

  Maxwell, Simon R J ^a   Webb, David J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; ROFECOXIB; VALDECOXIB;

CARDIOTOXICITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHRONIC PAIN; CLINICAL TRIAL; COLON ADENOMA; COST EFFECTIVENESS ANALYSIS; DIGESTIVE SYSTEM ULCER; DRUG APPROVAL; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG LABELING; DRUG MARKETING; DRUG SAFETY; DRUG SELECTIVITY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; NOTE; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; STATISTICAL SIGNIFICANCE; STROKE; THROMBOCYTE AGGREGATION; THROMBOCYTOPOIESIS; THROMBOEMBOLISM; ULCER PERFORATION;

EID: 13444282305     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)70247-6     Document Type: Note

References (17)

1. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 340:1999;1888-1899
2. Hawkey CJ. COX-2 inhibitors. Lancet. 353:1999;307-314
3. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 343:2000;1520-1528
4. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled study. JAMA. 284:2000;1247-1255
5. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 286:2001;954-959
6. Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 363:2004;1751-1756
7. Merck. Merck announces voluntary withdrawal of Vioxx®. Sept 30, 2004: http://www.merck.com/newsroom/press_releases/product/2004_0930.html (accessed Jan 19, 2005).
8. Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 364:2004;2021-2029
9. Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005; 142: http://www.acponline.org/journals/annals/myo_infar.pdf (accessed Jan 19, 2005).
10. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA. 96:1999;272-277
11. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 360:2002;1071-1073
12. Emery P, Hawkey CJ, Moore A. Prescribing in the UK. Lancet. 357:2001;809
13. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 18:2004;790-804
14. Schnitzer TJ, Burmester GR, Mysler E, on behalf of the TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364: 665-74.
15. Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg. 125:2003;1481-1487
16. Pfizer. Pfizer statement on new information regarding cardiovascular safety of Celebrex. Dec 17, 2005: http://www.pfizer.com/are/investors_releases/ 2004pr/mn_2004_1217.cfm (accessed Jan 19, 2005).
17. Horton R, Smith R. Time to register randomised trials. Lancet. 354:1999;1138-1139